公开(公告)号：AT419253T

公开(公告)日：2009-01-15

申请号：AT04779180

申请日：2004-07-26

Applicant: ABBOTT LAB

Inventor： BETSCHMANN PATRICK ,  BURCHAT ANDREW ,  CALDERWOOD DAVID ,  CURTIN MICHAEL ,  DAVIDSEN STEVEN ,  DAVIS HEATHER ,  FREY ROBIN ,  HEYMAN HOWARD ,  HIRST GAVIN ,  HRNCIAR PETER ,  MICHAELIDES MICHAEL ,  MUCKEY MELANIE ,  RAFFERTY PAUL ,  WADA CAROL

IPC: C07D495/04 ,  A61K31/4355 ,  A61K31/4365 ,  A61P35/00 ,  C07D491/04 ,  C07D498/04

Abstract: Compounds having the formula are useful for inhibiting protein tyrosine kinases. The present invention also discloses methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.

公开(公告)号：AT469888T

公开(公告)日：2010-06-15

申请号：AT04776083

申请日：2004-05-21

Applicant: ABBOTT LAB

Inventor： DAI YUJIA ,  DAVIDSEN STEVEN ,  ERICSSON ANNA ,  HARTANDI KRESNA ,  JI ZHIQIN ,  MICHAELIDES MICHAEL

IPC: C07D231/56 ,  A61K31/416 ,  A61K31/42 ,  A61K31/4709 ,  A61P35/00 ,  C07D261/20 ,  C07D275/04 ,  C07D401/04 ,  C07D401/12 ,  C07D403/04 ,  C07D403/12 ,  C07D409/04 ,  C07D413/02

Abstract: Compounds having the formula are useful for inhibiting protein tyrosine kinases. The present invention also discloses methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.

公开(公告)号：DE69228932T2

公开(公告)日：1999-11-11

申请号：DE69228932

申请日：1992-07-14

Applicant: ABBOTT LAB

Inventor： SUMMERS JAMES ,  DAVIDSEN STEVEN ,  HOLMS JAMES ,  PIREH DAISY ,  HEYMAN H ,  MARTIN MICHAEL ,  STEINMAN DOUGLAS ,  SHEPPARD GEORGE ,  CARRERA GEORGE

IPC: A61K31/44 ,  A61K31/4406 ,  A61K49/00 ,  A61K49/06 ,  A61P1/04 ,  A61P7/02 ,  A61P7/06 ,  A61P9/02 ,  A61P11/06 ,  A61P17/06 ,  A61P29/00 ,  A61P37/06 ,  A61P37/08 ,  A61P43/00 ,  C07B47/00 ,  C07D213/69 ,  C07D487/04 ,  C07D498/04 ,  C07D513/04 ,  C07F5/00 ,  C07F13/00

Abstract: PCT No. PCT/US92/05890 Sec. 371 Date Dec. 2, 1993 Sec. 102(e) Date Dec. 2, 1993 PCT Filed Jul. 14, 1992 PCT Pub. No. WO93/01813 PCT Pub. Date Feb. 4, 1993.Indole compounds substituted at the 3-position by a 7-carbonyl(pyridin-3-yl)pyrrolo[1,2-c]thiazole, 7-carbonyl(pyridin-3-yl)pyrrolo[1,2-c]oxazole, or 7-carbonyl(pyridin-3-yl)pyrrolo[1,2-c]pyrrole group are potent antagionists of PAF and are useful in the treatment of PAF-related disorders including asthma, shock, respiratory distress syndrome, acute inflammation, transplanted organ rejection, gastrointesinal ulceration, allergic skin diseases, delayed cellular immunity, parturition, fetal lung maturation, and cellular differentiation.

公开(公告)号：ES2398074T3

公开(公告)日：2013-03-13

申请号：ES10164213

申请日：2004-05-21

Applicant: ABBOTT LAB

Inventor： DAI YUJIA ,  DAVIDSEN STEVEN ,  ERICSSON ANNA ,  HARTANDI KRESNA ,  JI ZHIQIN ,  MICHAELIDES MICHAEL

IPC: C07D231/56 ,  A61K31/416 ,  A61K31/42 ,  A61K31/423 ,  A61K31/428 ,  A61K31/4709 ,  A61P35/00 ,  C07D261/20 ,  C07D275/04 ,  C07D401/04 ,  C07D401/12 ,  C07D403/04 ,  C07D403/12 ,  C07D405/12 ,  C07D409/04 ,  C07D413/02

Abstract: El compuesto de fórmula (II) o una sal terapéuticamente aceptable del mismo, en la que X se selecciona entre el grupo que consiste en O y S; R1 y R2 se seleccionan independientemente entre el grupo que consiste en hidrógeno, alcoxi, alcoxialcoxi,alcoxialquilo, alquilo, ariloxi, ariloxialquilo, halo, haloalcoxi, haloalquilo, heterociclilo, heterociclilalquenilo,heterociclilalcoxi, heterociclilalquilo, heterocicliloxialquilo, hidroxi, hidroxialcoxi, hidroxialquilo, (NRaRb)alcoxi,(NRaRb)alquenilo, (NRaRb)alquilo, (NRaRb)carbonilalquenilo y (NRaRb)carbonilalquilo;R3 y R4 se seleccionan independientemente entre el grupo que consiste en hidrógeno, alcoxi, alquilo, halo,haloalcoxi, haloalquilo e hidroxi; L se selecciona entre el grupo que consiste en (CH2)mN(R7)C(O)N(R8)(CH2)n y CH2C(O)NR7, en la que m y nson independientemente 0 ó 1, y en la que cada grupo se dibuja con su extremo izquierdo unido al anillosustituido con R3 y R4.

公开(公告)号：DE69228932D1

公开(公告)日：1999-05-20

申请号：DE69228932

申请日：1992-07-14

Applicant: ABBOTT LAB

Inventor： SUMMERS JAMES ,  DAVIDSEN STEVEN ,  HOLMS JAMES ,  PIREH DAISY ,  HEYMAN H ,  MARTIN MICHAEL ,  STEINMAN DOUGLAS ,  SHEPPARD GEORGE ,  CARRERA GEORGE

IPC: A61K31/44 ,  A61K31/4406 ,  A61K49/00 ,  A61K49/06 ,  A61P1/04 ,  A61P7/02 ,  A61P7/06 ,  A61P9/02 ,  A61P11/06 ,  A61P17/06 ,  A61P29/00 ,  A61P37/06 ,  A61P37/08 ,  A61P43/00 ,  C07B47/00 ,  C07D213/69 ,  C07D487/04 ,  C07D498/04 ,  C07D513/04 ,  C07F5/00 ,  C07F13/00

Abstract: PCT No. PCT/US92/05890 Sec. 371 Date Dec. 2, 1993 Sec. 102(e) Date Dec. 2, 1993 PCT Filed Jul. 14, 1992 PCT Pub. No. WO93/01813 PCT Pub. Date Feb. 4, 1993.Indole compounds substituted at the 3-position by a 7-carbonyl(pyridin-3-yl)pyrrolo[1,2-c]thiazole, 7-carbonyl(pyridin-3-yl)pyrrolo[1,2-c]oxazole, or 7-carbonyl(pyridin-3-yl)pyrrolo[1,2-c]pyrrole group are potent antagionists of PAF and are useful in the treatment of PAF-related disorders including asthma, shock, respiratory distress syndrome, acute inflammation, transplanted organ rejection, gastrointesinal ulceration, allergic skin diseases, delayed cellular immunity, parturition, fetal lung maturation, and cellular differentiation.